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There was indeed no washout period of enalapril; how-
ever, only 27% of patients were on enalapril at entry [29%
in the MMF group and 23% in the placebo group; P =
0.7867 (chi-square)]. The lack of impact of MMF on renal
function noted in our study is difficult to explain by this
phenomenon.
Because of small sample size, the data were ana-
lyzed using nonparametric statistics (Wilcoxon rank sum
test, chi-square test, linear mixed models), applicable to
both normal and non-normal distributed sample data
[2, 3].
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Hepatic iron in hemodialysis
patients
To the Editors: Canavese et al [1] reported that hepatic
iron overload is common in hemodialysis patients, and
suggested a reevaluation of acceptable iron parameters.
This was a well-designed study, and the work is an impor-
tant contribution to our knowledge on iron storage in this
patient population. It should be noted, however, that it
may not be reasonable to extrapolate these results to the
general hemodialysis population. To properly answer the
question of how prevalent iron overload is in hemodial-
ysis patients, an unselected group of patients should be
studied. This was not true of Canavese’s cohort. Thirty
out of 40 subjects (75%) had to discontinue 15 months
of continuous intravenous iron therapy due to serum fer-
ritin >500 ng/mL. Therefore, there was a strong selection
bias towards an iron-overloaded subpopulation.
It should be noted that the major finding of this study,
that many patients on hemodialysis had mild to moderate
hepatic iron “overload,” is not a new finding. More than
20 years ago, Ali et al [2] and Gokal et al [3] performed au-
topsy studies and found excess hepatic iron in hemodialy-
sis patients. In contrast to Canavese’s study, these authors
had access to hepatic tissue, allowing them to determine if
the excess iron was found in association with tissue dam-
age. Ali found significant iron excess in the livers of 48%
of subjects. Importantly, no liver pathology or damage
was found, even in cases of severe iron overload. Indeed,
anecdotally, there does not appear to be any excess preva-
lence of cirrhosis among hemodialysis patients. The fact
that hepatic tissue damage does not seem to coexist with
hepatic iron overload suggests that hepatic iron excess,
as found by Ali, Gokal, and Canavese, may simply be a
reflection of shifted iron pools. Indeed, an elevated serum
ferritin (iron storage marker) concurrent with low or nor-
mal transferrin saturation (iron circulation marker) is a
frequent finding in hemodialysis patients, consistent with
a shift of iron pools away from the circulation and into
storage tissues. Inflammation may be the key central link
and driver of this process. Recently, a strong association
was found between measures of inflammation and serum
ferritin [4, 5]. The phenomenon may best be understood
as inflammation leading to a state of reticuloendothelial
blockade that causes hemodialysis patients to have in-
creased hepatic storage of poorly mobile iron.
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The impact of serum uric acid
on cardiovascular outcomes in
the LIFE study
To the Editor: The analysis of the role of serum uric
acid (SUA) levels in the Losartan In tervention for End-
point reduction in hypertension study (LIFE) study is of
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considerable interest [1]. Briefly, 29% of the superiority
of losartan (compared with atenolol) on the primary com-
posite end point was attributed to a fall in SUA.
In the Greek Atorvastatin and Coronary-Heart dis-
ease Evaluation (GREACE) study, using atorvastatin to
achieve the low-density lipoprotein cholesterol (LDL-C)
goal for high-risk patients (100 mg/dL; 2.6 mmol/L) was
associated with a significant (P < 0.0001) fall in SUA lev-
els [2]. In contrast, a significant (P < 0.0001) increase in
SUA occurred in the ‘usual care’ group, where the ma-
jority did not achieve the LDL-C target. Every 1 mg/dL
fall in SUA resulted in a decreased hazard ratio (0.76;
95% CI 0.62–0.89; P = 0.001) for vascular events. The fall
in SUA was attributed to a parallel reduction in serum
creatinine (SCr).
A decrease in SUA and SCr was seen in 103 periph-
eral arterial disease patients taking simvastatin [3]. In the
Heart Protection Study, the simvastatin group had a sig-
nificantly smaller (P < 0.0001) increase in SCr than the
placebo group [4].
In the LIFE study, the fall in SUA levels may be at-
tributed to the specific uricosuric action of losartan be-
cause the final SCr levels were similar in the losartan and
atenolol groups. Therefore, statins and losartan probably
lower SUA levels via different mechanisms, thus raising
the possibility of an additive effect.
The use of drugs that lower SUA levels may signifi-
cantly lower the risk of vascular events [5].
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Heterozygous NPHS1 or
NPHS2 mutations in
responsive nephrotic syndrome
and the multifactorial origin of
proteinuria
To the Editor: Lahdenkari et al [1] described heterozy-
gous NPHS1 mutations in 2 out of 25 patients with min-
imal change nephropathy. Compound heterozygous mu-
tations were present in 2 adults with the same condition.
Similar clinical features were already reported in few
nephrotic patients with heterozygous NPHS2 mutations,
and in 1 child with heterozygous NPHS1 mutation asso-
ciated with the NPHS2 R229Q variant [2]. The body of
evidence on the topics is growing, and other confirmatory
papers are now appearing [3]. Therefore, while homozy-
gous and/or compound heterozygous mutations of these
2 genes are associated with strict steroid/cyclosporine re-
sistance, patients with a single mutation may respond to
therapy and have good long-term outcome. Because in-
herited conditions associated with NPHS1 or NPHS2 fol-
low a recessive trait, two issues remain unresolved. One
is why heterozygous carriers develop proteinuria, and the
second is the response to drugs.
As authors correctly discussed, mutations in other
genes could explain proteinuria as a part of a complex
inheritance (point 1). However, a complex inheritance
does not explain sensitivity to drugs that should better
be explained on the basis of a multifactorial mechanism
(point 2). Data on permeability activity in patients with
focal glomerulosclerosis and mutations of NPHS2 sup-
ports this possibility [4]. In spite of some unresolved prob-
lems, it seems worth mentioning the clinical impact of
these observations. They also suggest the implication of
nongenetic factors and open up to a multifactorial genesis
of proteinuria.
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